Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.17
Equity-to-Asset	0.06
Debt-to-Equity	10.37
Debt-to-EBITDA	4.37
Interest Coverage	2.75
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.37	Distress Grey Safe
Beneish M-Score	-2.44	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.7
	3-Year EBITDA Growth Rate	7.7
	3-Year EPS without NRI Growth Rate	14.9
	3-Year FCF Growth Rate	-6.6
	3-Year Book Growth Rate	-10.6
	Future 3-5Y EPS without NRI Growth Rate	5.25
	Future 3-5Y Total Revenue Growth Rate	4.2

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	50.43
	9-Day RSI	48.78
	14-Day RSI	46.65
	6-1 Month Momentum %	4.47
	12-1 Month Momentum %	17.99

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.65
	Quick Ratio	1.13
	Cash Ratio	0.6
	Days Inventory	254.5
	Days Sales Outstanding	79.09
	Days Payable	60.92

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.21
	Dividend Payout Ratio	0.47
	3-Year Dividend Growth Rate	10
	Forward Dividend Yield %	3.35
	5-Year Yield-on-Cost %	5.19
	3-Year Average Share Buyback Ratio	2.5
	Shareholder Yield %	-13.58

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.02
	Operating Margin %	28.01
	Net Margin %	23.83
	FCF Margin %	26.11
	ROE %	113.16
	ROA %	7.78
	ROIC %	13.52
	ROC (Joel Greenblatt) %	180.71
	ROCE %	15.35
	Years of Profitability over Past 10-Year	10

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	21.62
	Forward PE Ratio	13.95
	PE Ratio without NRI	14.83
	Shiller PE Ratio	22.71
	Price-to-Owner-Earnings	17.38
	PEG Ratio	2.7
	PS Ratio	5.15
	PB Ratio	23.19
	Price-to-Free-Cash-Flow	19.74
	Price-to-Operating-Cash-Flow	17.14
	EV-to-EBIT	18.47
	EV-to-Forward-EBIT	13.26
	EV-to-EBITDA	13.39
	EV-to-Forward-EBITDA	10.76
	EV-to-Revenue	7.03
	EV-to-Forward-Revenue	6.05
	EV-to-FCF	26.93
	Price-to-Projected-FCF	1.31
	Price-to-DCF (Earnings Based)	0.93
	Price-to-DCF (FCF Based)	1.63
	Price-to-Median-PS-Value	0.93
	Price-to-Peter-Lynch-Fair-Value	2.45
	Earnings Yield (Greenblatt) %	5.41
	FCF Yield %	5.08
	Forward Rate of Return (Yacktman) %	11.71

GF Value: $291.6

AMGN

Warning Signs

Warning! GuruFocus detected 6 Severe warning signs with AMGN. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.